CN110121359A - 人血浆培养基 - Google Patents

人血浆培养基 Download PDF

Info

Publication number
CN110121359A
CN110121359A CN201780081328.2A CN201780081328A CN110121359A CN 110121359 A CN110121359 A CN 110121359A CN 201780081328 A CN201780081328 A CN 201780081328A CN 110121359 A CN110121359 A CN 110121359A
Authority
CN
China
Prior art keywords
medium
cells
cell
assay
basal medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780081328.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·M·怀特黑德
J·坎托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of CN110121359A publication Critical patent/CN110121359A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/32—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780081328.2A 2016-11-11 2017-11-13 人血浆培养基 Pending CN110121359A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421074P 2016-11-11 2016-11-11
US62/421,074 2016-11-11
PCT/US2017/061377 WO2018089928A1 (en) 2016-11-11 2017-11-13 Human plasma-like medium

Publications (1)

Publication Number Publication Date
CN110121359A true CN110121359A (zh) 2019-08-13

Family

ID=62110050

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780081328.2A Pending CN110121359A (zh) 2016-11-11 2017-11-13 人血浆培养基

Country Status (6)

Country Link
US (2) US11453858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538151B1 (cg-RX-API-DMAC7.html)
JP (1) JP7406990B2 (cg-RX-API-DMAC7.html)
CN (1) CN110121359A (cg-RX-API-DMAC7.html)
CA (1) CA3043640A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018089928A1 (cg-RX-API-DMAC7.html)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111334472A (zh) * 2020-03-27 2020-06-26 郑州鲲鹏健康科技有限公司 Pbmc体外3d胶原蛋白水凝胶培养基及其制备方法
CN112029718A (zh) * 2020-09-17 2020-12-04 英科博雅基因科技(天津)有限公司 无血清驯化培养间充质干细胞的方法和所用的培养基
CN113005082A (zh) * 2019-12-20 2021-06-22 依科赛生物科技(太仓)有限公司 一种t细胞无血清培养基及其应用
CN113230391A (zh) * 2021-05-13 2021-08-10 杭州医学院 尿酸酶在制备抗肿瘤药物增敏剂中的应用
CN114317446A (zh) * 2021-12-30 2022-04-12 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
CN114457149A (zh) * 2022-01-05 2022-05-10 中南大学湘雅二医院 筛选别嘌醇耐受的基因甲基化标志物的应用及检测试剂
CN114634910A (zh) * 2022-03-09 2022-06-17 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种胃癌细胞的培养基及其培养方法
CN116751737A (zh) * 2023-08-16 2023-09-15 上海科新生物技术股份有限公司 无血清无蛋白培养基和制备方法及其应用
CN119286765A (zh) * 2024-12-10 2025-01-10 山东伯桢生物科技有限公司 类器官基础培养基及维持和促进类器官生长的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US20220003750A1 (en) * 2018-12-01 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients
WO2020264072A1 (en) * 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
US12297451B1 (en) * 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN116515754B (zh) * 2023-03-17 2024-01-30 创芯国际生物科技(广州)有限公司 一种脂肪肉瘤类器官、培养基及培养方法
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
CN118240744B (zh) * 2024-03-06 2024-11-26 上海迈邦生物科技有限公司 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
CN118374562B (zh) * 2024-06-26 2024-09-03 山东润德生物科技有限公司 一种用于制备n-乙酰氨基葡萄糖的发酵培养基
WO2026142011A1 (ko) * 2024-12-27 2026-07-02 주식회사 스웬 생체 샘플 기반 추모 물품 제작 장치 및 방법

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001202A1 (en) * 1991-07-05 1993-01-21 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO2003064630A2 (en) * 2002-04-08 2003-08-07 Lonza Biologics Plc. Cell culture medium
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20110244502A1 (en) * 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
US20120258439A1 (en) * 2011-04-11 2012-10-11 Ali Bin M Abdullah Jaffar Protein-Free Culture Media Products
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
US20130029368A1 (en) * 2011-07-29 2013-01-31 Steven Kattman Metabolic maturation in stem cell-derived tissue cells
CN102994441A (zh) * 2012-09-19 2013-03-27 上海瀚康生物医药科技有限公司 一种细胞培养基及其制备方法和用途
US20150259425A1 (en) * 2012-10-01 2015-09-17 Abbvie Biotherapeutics Inc. Compositions and methods for producing glycoproteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62278980A (ja) * 1986-05-29 1987-12-03 Morinaga & Co Ltd 細胞増殖因子
DE544887T1 (de) 1991-06-17 1994-02-03 Life Technologies Inc Technik zur konzentration von kulturmedien.
DK0996636T3 (da) 1997-07-23 2005-04-25 Univ Leiden HA-1-antigenet
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
JP2008109866A (ja) 2006-10-30 2008-05-15 Jms Co Ltd 培地添加剤、この培地添加剤を含む培地、及びこの培地を用いた細胞の培養方法
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
ES2664219T3 (es) 2011-01-28 2018-04-18 Immunic Ag Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria
WO2012125533A1 (en) 2011-03-14 2012-09-20 Wellstat Therapeutics Corporation 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
WO2014017643A1 (ja) 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
US20190100725A1 (en) * 2016-03-18 2019-04-04 Institute Of Biophysics, Chinese Academy Of Sciences Cell culture medium and culture medium supplement
WO2018089928A1 (en) 2016-11-11 2018-05-17 Whitehead Institute For Biomedical Research Human plasma-like medium

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001202A1 (en) * 1991-07-05 1993-01-21 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO2003064630A2 (en) * 2002-04-08 2003-08-07 Lonza Biologics Plc. Cell culture medium
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20110244502A1 (en) * 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
US20120258439A1 (en) * 2011-04-11 2012-10-11 Ali Bin M Abdullah Jaffar Protein-Free Culture Media Products
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
US20130029368A1 (en) * 2011-07-29 2013-01-31 Steven Kattman Metabolic maturation in stem cell-derived tissue cells
CN102994441A (zh) * 2012-09-19 2013-03-27 上海瀚康生物医药科技有限公司 一种细胞培养基及其制备方法和用途
US20150259425A1 (en) * 2012-10-01 2015-09-17 Abbvie Biotherapeutics Inc. Compositions and methods for producing glycoproteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
钱雪冰等: "氟尿嘧啶及其衍生物与合并用药的探讨", 《医药导报》 *
钱雪冰等: "氟尿嘧啶及其衍生物与合并用药的探讨", 《医药导报》, vol. 15, no. 03, 15 June 1996 (1996-06-15), pages 140 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113005082A (zh) * 2019-12-20 2021-06-22 依科赛生物科技(太仓)有限公司 一种t细胞无血清培养基及其应用
CN111334472A (zh) * 2020-03-27 2020-06-26 郑州鲲鹏健康科技有限公司 Pbmc体外3d胶原蛋白水凝胶培养基及其制备方法
CN112029718A (zh) * 2020-09-17 2020-12-04 英科博雅基因科技(天津)有限公司 无血清驯化培养间充质干细胞的方法和所用的培养基
CN112029718B (zh) * 2020-09-17 2023-04-07 深圳博雅感知药业有限公司 无血清驯化培养间充质干细胞的方法和所用的培养基
CN113230391A (zh) * 2021-05-13 2021-08-10 杭州医学院 尿酸酶在制备抗肿瘤药物增敏剂中的应用
CN114317446B (zh) * 2021-12-30 2023-12-05 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
CN114317446A (zh) * 2021-12-30 2022-04-12 广州康盛生物科技股份有限公司 一种无血清培养基用添加剂及其应用
CN114457149A (zh) * 2022-01-05 2022-05-10 中南大学湘雅二医院 筛选别嘌醇耐受的基因甲基化标志物的应用及检测试剂
CN114634910A (zh) * 2022-03-09 2022-06-17 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种胃癌细胞的培养基及其培养方法
CN114634910B (zh) * 2022-03-09 2024-03-08 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种胃癌细胞的培养基及其培养方法
CN116751737B (zh) * 2023-08-16 2023-11-14 上海科新生物技术股份有限公司 无血清无蛋白培养基和制备方法及其应用
CN116751737A (zh) * 2023-08-16 2023-09-15 上海科新生物技术股份有限公司 无血清无蛋白培养基和制备方法及其应用
CN119286765A (zh) * 2024-12-10 2025-01-10 山东伯桢生物科技有限公司 类器官基础培养基及维持和促进类器官生长的方法

Also Published As

Publication number Publication date
EP3538151B1 (en) 2024-06-26
WO2018089928A1 (en) 2018-05-17
US20190352598A1 (en) 2019-11-21
US11453858B2 (en) 2022-09-27
EP3538151A4 (en) 2020-06-10
US20230051644A1 (en) 2023-02-16
CA3043640A1 (en) 2018-05-17
JP7406990B2 (ja) 2023-12-28
EP3538151A1 (en) 2019-09-18
JP2020501522A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US20230051644A1 (en) Human plasma-like medium
Koundinya et al. Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers
Gorospe et al. Mitochondrial membrane potential acts as a retrograde signal to regulate cell cycle progression
Cantor et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase
Tajan et al. A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3
Huang et al. Role of glutamine and interlinked asparagine metabolism in vessel formation
Podtcheko et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
Hill et al. Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways
Valvezan et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
CA2318379A1 (en) Identification of substances that modify cellular secretory function
TW201726169A (zh) Pd-1訊息抑制劑之併用療法
EP3525775B1 (en) Arginine and its use as a t cell modulator
JP2020501522A5 (cg-RX-API-DMAC7.html)
Franzolin et al. The pyrimidine nucleotide carrier PNC1 and mitochondrial trafficking of thymidine phosphates in cultured human cells
Drago et al. DHFR2 RNA directly regulates dihydrofolate reductase and its expression level impacts folate one carbon metabolism
Taricani et al. Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase
Bornkamm et al. Burkitt’s Lymphoma and Early B Cell Transformation as Paradigms of How Epstein-Barr Virus Overcomes Apoptosis and Ferroptosis
US20200384115A1 (en) Targeted delivery to beta cells
Abir et al. Glycolytic flux sustains human Th1 identity and effector function via STAT1 glycosylation
US20260027190A1 (en) Ovarian tumor deubiquitinase oxidation and uses thereof
Real Small Molecule Interactions Directed to the Scaffold Kinase Suppressor of Ras Modulate MAPK Signaling in Cancer
Perea Protective eIF2α Signaling Promotes Adaptive Mitochondrial Remodeling During ER Stress
Huggler Investigating Genetic and Environmental Contributions to Cell Growth
Villarreal Exploring novel roles of metabolic enzymes MTHFD2 and PFKFB3 in cancer genome stability and their potential as anticancer therapeutic targets
Ruffolo Metabolic reprogramming in Fanconi Anemia-deficient head and neck squamous cell carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination